KG&L Capital Management LLC Decreases Holdings in Johnson & Johnson $JNJ

KG&L Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 26.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,615 shares of the company’s stock after selling 6,715 shares during the period. Johnson & Johnson comprises 0.9% of KG&L Capital Management LLC’s investment portfolio, making the stock its 25th biggest position. KG&L Capital Management LLC’s holdings in Johnson & Johnson were worth $3,437,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Clark Asset Management LLC increased its holdings in Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after buying an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in shares of Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after acquiring an additional 94,957 shares during the last quarter. Avanza Fonder AB raised its position in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Talbot Financial LLC boosted its holdings in Johnson & Johnson by 4.6% in the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after purchasing an additional 6,143 shares during the period. Finally, Winnow Wealth LLC bought a new stake in Johnson & Johnson during the second quarter valued at $295,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Nipocalimab phase II success — JNJ reported nipocalimab met key endpoints in a Phase IIb SLE study, supporting a planned move to Phase III and de‑risking a late‑stage autoimmune program that could add future revenue. JNJ’s Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
• Positive Sentiment: MedTech growth catalyst — J&J MedTech submitted its Ottava surgical robot to the FDA, advancing a high‑margin growth avenue in robotics/surgery that could expand addressable market if cleared. Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Positive Sentiment: Research collaboration in cardiac gene therapy — JNJ is partnering with Lexeo Therapeutics to test localized AAV delivery using Impella technology, which could accelerate novel cardiac programs and strengthen cardiovascular R&D capabilities. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology
• Positive Sentiment: Analyst and media support — Barclays raised its JNJ price target (to $217) and Wolfe Research lifted its target to $240; high‑profile bullish commentary (Jim Cramer called it a “terrific entry point”) may attract buyers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs Wolfe Research Increases Johnson & Johnson Price Target to $240.00 Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”
• Neutral Sentiment: Innovative Medicines resilience — analysts note J&J’s Innovative Medicines segment remains resilient with key drugs offsetting some pressures; watch Q4 details for cadence and guidance. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch
• Neutral Sentiment: Macro tailwind for health care — sector rotation into health-care and dividend/value themes is supportive of JNJ stock but is a broader factor rather than company‑specific. Experts See Health Care’s Rally Continuing. This ETF Is Proof
• Negative Sentiment: Commercial headwinds — continued pressure from Stelara biosimilars and Medicare Part D dynamics could weigh on sales and near‑term margins in immunology/dermatology franchises. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch

Analyst Ratings Changes

JNJ has been the subject of several research reports. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Wolfe Research upped their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Citigroup increased their target price on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $212.62.

Johnson & Johnson Price Performance

Shares of JNJ opened at $205.78 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The stock’s fifty day moving average is $202.56 and its 200-day moving average is $184.15. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $495.79 billion, a price-to-earnings ratio of 19.86, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.